Research programme: checkpoint kinase 1 inhibitors - Vernalis

Drug Profile

Research programme: checkpoint kinase 1 inhibitors - Vernalis

Alternative Names: V 158411

Latest Information Update: 10 Apr 2012

Price : $50

At a glance

  • Originator Vernalis
  • Class
  • Mechanism of Action Checkpoint kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 03 Apr 2012 V 158411 is available for partnering (www.vernalis.com)
  • 27 Aug 2010 Preclinical development is ongoing in United Kingdom
  • 19 Nov 2009 Preclinical pharmacodynamics, pharmacokinetics and safety data in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top